Sanofi’s Eloxatin Gets Survival Label
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears add-on to claims for colorectal cancer drug.
You may also be interested in...
Eloxatin Adds Adjuvant Colorectal Cancer Claim Based On Disease-Free Survival
Sanofi-Aventis' agent is the first oncologic to be approved for an adjuvant colorectal cancer indication based on a disease-free survival endpoint. It did not demonstrate benefit in overall survival after a median follow-up of four years.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.